Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma.
Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma.
复制标题
DOI：
10.1038/bjc.2012.525
复制
发表时间：
2012-12-04
影响因子：
8.8
通讯作者：
Newbury, S. F.
中科院分区：
文献类型：
--
作者：
Jones, C. I.;Zabolotskaya, M. V.;King, A. J.;Stewart, H. J. S.;Horne, G. A.;Chevassut, T. J.;Newbury, S. F.
多发性骨髓瘤是一种以骨髓恶性浆细胞克隆性增殖、血或尿中单克隆性副蛋白及相关器官功能障碍为特征的浆细胞疾病。它约占癌症的1%，占血液病癌症的13%。骨髓瘤起源于一种称为未确定意义的单克隆性伽马病(MGUS)的单克隆性浆细胞的无症状增殖。对三组患者和正常对照组的血清样本进行了microRNA表达谱分析。利用TaqMan定量逆转录聚合酶链式反应对9个被检测为有希望的生物标志物的microRNAs进行了验证。用标准曲线将血清中的microRNA水平归一化，以确定L血清中每μ的microRNA数量。三种血清microRNAs miR-720、miR-1308和miR-1246有可能作为骨髓瘤的诊断生物标志物。MiR-720和miR-1308的联合使用为区分正常健康对照以及患有无关疾病的患者与癌前骨髓瘤和骨髓瘤患者提供了一种强大的诊断工具。此外，miR-1246和miR-1308的联合检测可以区分MGUS和骨髓瘤患者。我们已经开发出一种使用从血清中提取的microRNAs的生物标记物，这有可能成为多发性骨髓瘤的诊断和预后工具。
Multiple myeloma is a plasma cell disorder that is characterised by clonal proliferation of malignant plasma cells in the bone marrow, monoclonal paraprotein in the blood or urine and associated organ dysfunction. It accounts for approximately 1% of cancers and 13% of haematological cancers. Myeloma arises from an asymptomatic proliferation of monoclonal plasma cells termed monoclonal gammopathy of undetermined significance (MGUS). MicroRNA expression profiling of serum samples was performed on three patient groups as well as normal controls. Validation of the nine microRNAs detected as promising biomarkers was carried out using TaqMan quantitative reverse transcription PCR. MicroRNA levels in serum were normalised using standard curves to determine the numbers of microRNAs per μl of serum. Three serum microRNAs, miR-720, miR-1308 and miR-1246, were found to have potential as diagnostic biomarkers in myeloma. Use of miR-720 and miR-1308 together provides a powerful diagnostic tool for distinguishing normal healthy controls, as well as patients with unrelated illnesses, from pre-cancerous myeloma and myeloma patients. In addition, the combination of miR-1246 and miR-1308 can distinguish MGUS from myeloma patients. We have developed a biomarker signature using microRNAs extracted from serum, which has potential as a diagnostic and prognostic tool for multiple myeloma.
登录
查看更多内容
DOI：
10.1186/bcr2766
发表时间：
2010
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Roth C;Rack B;Müller V;Janni W;Pantel K;Schwarzenbach H
通讯作者：
Schwarzenbach H
影响因子：
6.1
作者：
Neal, Calida S.;Michael, Michael Z.;Gleadle, Jonathan M.
通讯作者：
Gleadle, Jonathan M.
DOI：
10.1073/pnas.0806202105
发表时间：
2008-09-02
影响因子：
11.1
作者：
Pichiorri, Flavia;Suh, Sung-Suk;Croce, Carlo M.
通讯作者：
Croce, Carlo M.
影响因子：
3.7
作者：
Hunter, Melissa Piper;Ismail, Noura;Zhang, Xiaoli;Aguda, Baltazar D.;Lee, Eun Joo;Yu, Lianbo;Xiao, Tao;Schafer, Jeffrey;Lee, Mei-Ling Ting;Schmittgen, Thomas D.;Nana-Sinkam, S. Patrick;Jarjoura, David;Marsh, Clay B.
通讯作者：
Marsh, Clay B.
影响因子：
5.8
作者：
Heneghan, Helen M.;Miller, Nicola;Kerin, Michael J.
通讯作者：
Kerin, Michael J.